Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (91-100 of 250) with videos related to

Pageof 25
Sort By:
Haematologica|April 12, 2003
Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 studyAlbert Oriol, Josep-Maria Ribera, Jordi Esteve, et al.
Haematologica|April 26, 2014
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapyMaría-Victoria Mateos, Sara Bringhen, Paul G Richardson, et al.
British Journal of Haematology|December 23, 2016
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myelomaNoopur S Raje, Philippe Moreau, Evangelos Terpos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2010
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myelomaMaría Victoria Mateos, Maria Teresa Cibeira, Paul G Richardson, et al.
Blood|July 5, 2019
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Maria-Victoria Mateos, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2022
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label studyMaría-Victoria Mateos, Miguel-Teodoro Hernández, Carlos Salvador, et al.
Bone Marrow Transplantation|August 18, 2021
Predictors of return to work after autologous stem cell transplantation in patients with multiple myelomaMiquel Granell, Alicia Senín, Anna Barata, et al.
European Journal of Haematology|November 8, 2006
Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemiaJuan-Manuel Sancho, Josep-Maria Ribera, Blanca Xicoy, et al.
British Journal of Haematology|April 6, 2021
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trialTorben Plesner, Meletios A Dimopoulos, Albert Oriol, et al.
Medicina Clinica|September 3, 2005
[Prevalence and prognostic significance of myeloid markers in adults with high-risk acute lymphoblastic leukemia]Esther Plensa, Josep Maria Ribera, Albert Oriol, et al.
Pageof 25

Showing results (91-100 of 250) with videos related to

Sort By:
Pageof 25
Haematologica|April 12, 2003
Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 studyAlbert Oriol, Josep-Maria Ribera, Jordi Esteve, et al.
Haematologica|April 26, 2014
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapyMaría-Victoria Mateos, Sara Bringhen, Paul G Richardson, et al.
British Journal of Haematology|December 23, 2016
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myelomaNoopur S Raje, Philippe Moreau, Evangelos Terpos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2010
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myelomaMaría Victoria Mateos, Maria Teresa Cibeira, Paul G Richardson, et al.
Blood|July 5, 2019
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Maria-Victoria Mateos, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2022
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label studyMaría-Victoria Mateos, Miguel-Teodoro Hernández, Carlos Salvador, et al.
Bone Marrow Transplantation|August 18, 2021
Predictors of return to work after autologous stem cell transplantation in patients with multiple myelomaMiquel Granell, Alicia Senín, Anna Barata, et al.
European Journal of Haematology|November 8, 2006
Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemiaJuan-Manuel Sancho, Josep-Maria Ribera, Blanca Xicoy, et al.
British Journal of Haematology|April 6, 2021
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trialTorben Plesner, Meletios A Dimopoulos, Albert Oriol, et al.
Medicina Clinica|September 3, 2005
[Prevalence and prognostic significance of myeloid markers in adults with high-risk acute lymphoblastic leukemia]Esther Plensa, Josep Maria Ribera, Albert Oriol, et al.
Pageof 25